Current Management of NAFLD
| Autor: | Mihai Alexandru Munteanu, Petru Adrian Mircea, Georgiana Nagy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Pathology education.field_of_study business.industry Fatty liver Population Alternative medicine Gastroenterology NASH Reviews non-alcoholic fatty liver disease General Medicine Disease medicine.disease Chronic liver disease Insulin resistance Current management NAFLD medicine non-alcoholic steatohepatitis Steatohepatitis Intensive care medicine education business fatty liver |
| Zdroj: | Clujul Medical |
| ISSN: | 2066-8872 1222-2119 |
| Popis: | Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. It affects about 1 billion individuals worldwide. While people with simple steatosis have no higher risk of death than the general population, people with non-alcoholic steatohepatitis are at increased risk of death compared to general population. Current management for NAFLD includes diet and lifestyle changes, management of underlying metabolic risk factors and pharmacological therapies. The objective of therapy is to prevent the complications. The problem with dietary and lifestyle interventions is that they are hard to implement. Compliance is the key. Until now, there is still no approved drug for the treatment of NAFLD. Insulin resistance is the main target of pharmacological therapy, but the question that we ask ourselves as physicians is who should receive medical treatment among NAFLD patients and for how long. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|